Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:00:46.203Z.
Calculation as of: 2026-10-06T15:00:46.203Z.
Quote observation: 2026-10-06T15:00:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.42M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.05M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.29M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.44M
EV/EBITDA Ratio
N/A
TTM Avg
20.17x
3Y Avg
20.17x
5Y Avg
20.17x
Market Cap
$107.28M
EV/EBITDA Ratio
N/A
TTM Avg
20.46x
3Y Avg
22.62x
5Y Avg
53.44x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.42M | N/A | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $110.05M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.07M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.29M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $107.75M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.44M | N/A | 20.17x | 20.17x | 20.17x |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.28M | N/A | 20.46x | 22.62x | 53.44x |
| Coya Therapeutics, Inc. (COYA)vs › | $113.30M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.48M | 0.49x | 1.56x | 17.47x | 77.57x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
